| 货号 | 4556/50 |
| 别名 | (3R,4R)-4-Methyl-3-(methyl-7H-pyrro |
| 供应商 | Tocris |
| 生物活性 | Potent JAK inhibitor (IC50 values are 1, 20, and 112 nM for JAK3, JAK2 and JAK1 respectively). Orally active immunosuppressant; exhibits efficacy in rodent rheumatoid arthritis models. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 纯度 | >99 % |
| 计算分子量 | 504.49 |
| 分子式 | C16H20N6O.C6 |
| 可溶性/溶解性 | Soluble to 100 mM in DMSO |
| 参考文献 | Dowtyet al (2013) Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J.Pharmacol.Exp.Ther. 348 165. PMID: 24218541. Flanaganet al (2010) Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J.Med.Chem. 53 8468. PMID: 21105711. Jianget al (2008) Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J.Med.Chem. 51 8012. PMID: 19053756. |